BioLineRx (BLRX) to Release Earnings on Tuesday

BioLineRx (NASDAQ:BLRX) is expected to be releasing its earnings data before the market opens on Tuesday, March 25th. Analysts expect BioLineRx to post earnings of ($4.20) per share and revenue of $7.72 million for the quarter.

BioLineRx Stock Up 4.7 %

NASDAQ:BLRX opened at $3.58 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The stock has a 50 day moving average of $3.69 and a 200-day moving average of $11.69. The firm has a market capitalization of $11.92 million, a PE ratio of -0.41 and a beta of 1.39. BioLineRx has a 52 week low of $2.88 and a 52 week high of $54.00.

Analyst Ratings Changes

A number of research analysts recently commented on BLRX shares. HC Wainwright lowered their price objective on BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a research note on Monday, November 25th. StockNews.com cut shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Tuesday, March 18th.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.